Medicenna Therapeutics Corp (MDNAF)

$1.10 +0.34 (44.74%)
Market Cap 91.75M
Revenue (ttm) 0.00
Net Income (ttm) -8.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 577,400
Avg Vol 55,678
Day's Range N/A - N/A
Shares Out 83.41M
Stochastic %K 100%
Beta 1.70
Analysts Strong Sell
Price Target $4.03

Company Profile

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, a long-acting interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; MDNA209, an IL-2/IL-15...

Industry: Biotechnology
Sector: Healthcare
Phone: 416 648 5555
Address:
2 Bloor Street West, Suite 903 7th Floor, Toronto, Canada
AuriniaBeach
AuriniaBeach Oct. 25 at 2:48 PM
$MDNAF Came across an article, last updated in June 2025, focusing on IL-2 superkines. See the table listing the many companies involved in IL-2 development, including Medicenna. Xilio has since discontinued XTX202. Unless I missed it, not one of the publicly traded companies from the list has had anywhere near MDNAF’s meteoric rise since Wednesday’s Takeda/Innovent deal announcement. https://www.labiotech.eu/more-news/il-2-smart-cytokines/
0 · Reply
rudazur2
rudazur2 Oct. 25 at 12:42 AM
$MDNAF after hours +40% is a bug ?
1 · Reply
Spartrap
Spartrap Oct. 24 at 9:38 PM
$MDNAF around November 23 there was a string of hot BP deals around ADC compounds. That triggered a massive revaluation of nearly all ADC biotechs. For instance ADCT went from $0.5 to $5 in the space of three months with no news. It saved the company from BK.
0 · Reply
Lytnup
Lytnup Oct. 24 at 8:03 PM
$MDNAF impressive trading, closing at the high of the day. Will be interesting to see what the next few weeks brings as we wait for December 10th. Thank you Dr Merchant, for your dedication to getting this company the recognition it deserves, and for getting promising compounds closer to those who need them.
0 · Reply
Spartrap
Spartrap Oct. 24 at 7:36 PM
$MDNAF $1.2B upfront cash in that Takeda deal, not even a full BO, is mind boggling. 3 compounds, one in P3, one P3 ready and one P1 stage IIUC. And the most coveted one is a very close cousin of MDNA113. It's very hard to not get the thrills seeing the commonalities as we are sitting at a sub-$100M MC. Probably room for $3-4 even before esmo data
3 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Oct. 24 at 7:27 PM
$MDNAF Let’s shoot for $1.60 CAN to start the weekend!
0 · Reply
NewbJackCity
NewbJackCity Oct. 24 at 7:18 PM
$MDNAF does anyone know if the company plans on uplisting to nasdaq soon?
1 · Reply
Usmccbr
Usmccbr Oct. 24 at 5:57 PM
$CISO $CISO , $ADUR, $CHHYF ,$MDNAF and others. Talk is cheap and many traders promise quality DD and solid trade alerts but don’t deliver. Penny is amazing and one of the great ones! Thanks for all your amazing work. The results speak for themselves. @PennyQueen
1 · Reply
NewbJackCity
NewbJackCity Oct. 24 at 4:36 PM
$MDNAF lol is the excitement over for the day?
1 · Reply
BigJon123
BigJon123 Oct. 24 at 2:38 PM
$MDNAF maybe the CEOs shoddy back room interviews are finally gaining some traction! My only regret is not buying more
2 · Reply
Latest News on MDNAF
No data available.
AuriniaBeach
AuriniaBeach Oct. 25 at 2:48 PM
$MDNAF Came across an article, last updated in June 2025, focusing on IL-2 superkines. See the table listing the many companies involved in IL-2 development, including Medicenna. Xilio has since discontinued XTX202. Unless I missed it, not one of the publicly traded companies from the list has had anywhere near MDNAF’s meteoric rise since Wednesday’s Takeda/Innovent deal announcement. https://www.labiotech.eu/more-news/il-2-smart-cytokines/
0 · Reply
rudazur2
rudazur2 Oct. 25 at 12:42 AM
$MDNAF after hours +40% is a bug ?
1 · Reply
Spartrap
Spartrap Oct. 24 at 9:38 PM
$MDNAF around November 23 there was a string of hot BP deals around ADC compounds. That triggered a massive revaluation of nearly all ADC biotechs. For instance ADCT went from $0.5 to $5 in the space of three months with no news. It saved the company from BK.
0 · Reply
Lytnup
Lytnup Oct. 24 at 8:03 PM
$MDNAF impressive trading, closing at the high of the day. Will be interesting to see what the next few weeks brings as we wait for December 10th. Thank you Dr Merchant, for your dedication to getting this company the recognition it deserves, and for getting promising compounds closer to those who need them.
0 · Reply
Spartrap
Spartrap Oct. 24 at 7:36 PM
$MDNAF $1.2B upfront cash in that Takeda deal, not even a full BO, is mind boggling. 3 compounds, one in P3, one P3 ready and one P1 stage IIUC. And the most coveted one is a very close cousin of MDNA113. It's very hard to not get the thrills seeing the commonalities as we are sitting at a sub-$100M MC. Probably room for $3-4 even before esmo data
3 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Oct. 24 at 7:27 PM
$MDNAF Let’s shoot for $1.60 CAN to start the weekend!
0 · Reply
NewbJackCity
NewbJackCity Oct. 24 at 7:18 PM
$MDNAF does anyone know if the company plans on uplisting to nasdaq soon?
1 · Reply
Usmccbr
Usmccbr Oct. 24 at 5:57 PM
$CISO $CISO , $ADUR, $CHHYF ,$MDNAF and others. Talk is cheap and many traders promise quality DD and solid trade alerts but don’t deliver. Penny is amazing and one of the great ones! Thanks for all your amazing work. The results speak for themselves. @PennyQueen
1 · Reply
NewbJackCity
NewbJackCity Oct. 24 at 4:36 PM
$MDNAF lol is the excitement over for the day?
1 · Reply
BigJon123
BigJon123 Oct. 24 at 2:38 PM
$MDNAF maybe the CEOs shoddy back room interviews are finally gaining some traction! My only regret is not buying more
2 · Reply
rudazur2
rudazur2 Oct. 24 at 2:36 PM
$MDNAF fuck that I asked to wait until tuesday stupid stock
0 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Oct. 24 at 2:31 PM
$MDNAF So thinly traded, it will be exponential when the news drops!
0 · Reply
Lytnup
Lytnup Oct. 24 at 1:48 PM
$MDNAF David has some more thoughts on MDNA’s enterprise value https://open.substack.com/pub/davidbakke/p/bean-counters-rebellion?r=10wt7d&utm_medium=ios
0 · Reply
NewbJackCity
NewbJackCity Oct. 24 at 1:37 PM
$MDNAF Buying right out the gate this morning I see? .86 x .88
0 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Oct. 24 at 1:36 PM
$MDNAF
0 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Oct. 24 at 11:46 AM
$MDNAF
0 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Oct. 23 at 10:20 PM
$MDNAF Great breakdown on how the current plays in the IL2 market just pumped our chances… https://open.substack.com/pub/davidbakke/p/everyones-talking-about-the-takeda?r=4sx38k&utm_medium=ios
0 · Reply
Vikingess
Vikingess Oct. 23 at 8:28 PM
$MDNAF is this just a random pump or do we actually thinking something significant might finally happen. Been waiting since 2023
3 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Oct. 23 at 1:32 PM
$MDNAF Let’s see some volume today!!!
0 · Reply
Spartrap
Spartrap Oct. 23 at 9:43 AM
$MDNAF for reference, here is the deal that got Fahar all excited and worked up. Not without cause tbf. https://www.fiercebiotech.com/biotech/takeda-pays-innovent-12b-upfront-rights-2-cancer-candidates
1 · Reply
NewbJackCity
NewbJackCity Oct. 22 at 7:30 PM
$MDNAF 10 minutes of questions towards the end of today’s presentation. Starting to gain some interest?
2 · Reply
rudazur2
rudazur2 Oct. 22 at 6:50 PM
$MDNAF FDA submission ???????
1 · Reply